IP Verse

Methods Of Administration Of Thrombopoietin Agonist Compounds - EP3127427

The patent EP3127427 was granted to Novartis on Jan 8, 2020. The application was originally filed on May 27, 2010 under application number EP16183711A. The patent is currently recorded with a legal status of "Revoked".

EP3127427

NOVARTIS
Application Number
EP16183711A
Filing Date
May 27, 2010
Status
Revoked
Aug 27, 2021
Grant Date
Jan 8, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSOct 8, 2020D YOUNGADMISSIBLE
ZENTIVA KSOct 8, 2020DENTONS UK AND MIDDLE EASTADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS5766581
DESCRIPTIONWO0189457
DESCRIPTIONWO03098992
DESCRIPTIONWO2008136843
OPPOSITIONWO0189457
OPPOSITIONWO2008136843
OPPOSITIONWO2010045310
OPPOSITIONWO2010129738
OPPOSITIONWO2010138656
SEARCHWO2008136843

Non-Patent Literature (NPL) Citations (33) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BASER ET AL., BLOOD, (1997), vol. 89, pages 3118 - 3128-
DESCRIPTION- BIOTHERAPY, (1998), vol. 10, no. 4, pages 269 - 277-
DESCRIPTION- FANUCCHI ET AL., NEW ENGL. J. MED., (1997), vol. 336, pages 404 - 409-
DESCRIPTION- HASEGAWA T. ET AL., INT. J. IMMUNOPHARM., (1996), vol. 18, pages 103 - 112-
DESCRIPTION- KUTER, D.J. ET AL., PROC. NATL. ACAD. SCI., (1994), vol. 91, pages 11104 - 11108-
DESCRIPTION- KUTER D.J. ET AL., THE ONCOLOGIST, (1996), vol. 1, pages 98 - 106-
DESCRIPTION- KUTER D. J., SEMINARS IN HEMATOLOGY, (2000), vol. 37, pages 41 - 49-
DESCRIPTION- LAURENZ JC. ET AL., COMP. BIOCHEM. & PHVS., PART A. PHYSIOLOGY, (1997), vol. 116, pages 369 - 377-
DESCRIPTION- LOK, S. ET AL., NATURE, (1994), vol. 369, pages 565 - 568-
DESCRIPTION- METCALF, NATURE, (1994), vol. 369, pages 519 - 520-
DESCRIPTION- SAUVAGE F.V. ET AL., NATURE, (1994), vol. 369, pages 533 - 538-
DESCRIPTION- SHIOTSU Y. ET AL., EXP. HEMAT., (1998), vol. 26, pages 1195 - 1201-
DESCRIPTION- VIGON ET AL., PROC. NATL. ACAD. SCI., (1992), vol. 89, pages 5640 - 5644-
DESCRIPTION- WENDING, F. ET AL., NATURE, (1994), vol. 369, pages 571 - 574-
OPPOSITION- A.Baranwal, J. L. A. Fraser, D. Jayawardene, A. Jagiello-Gruszfeld, I.Bondarenko, J. L. Mendoza, "Efficacy and Safety of Eltrombopag, a Novel Oral Platelet Growth Factor, on Platelet Counts in Patients With Cancer Receiving Carboplatin/Paclitaxel Chemotherapy", Poster presented at the 20th Anniversary International Multinational Association of Supportive Care in Cancer (MASCC) / International Society for Oral Oncology (ISOO) Symposium, St. Gallen, Switzerland, (200700628), XP055751503-
OPPOSITION- A.Kellum, A. Jagiello- Gruszfeld, I.N. Bondarenko, R. Patwardhan, C.Messam & Y. Mostafa Kamel, "A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of Eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors", Current Medical Research & Opinion, (20100000), vol. 26, no. 10, pages 2339 - 2346, XP055751511-
OPPOSITION- Anonymous, "CHMP ASSESSMENT REPORT FOR Revolade International Nonproprietary Name: eltrombopag- Procedure No. EMEA/H/C/001110", European Medicines Agency / EMA/CHMP/279276/2010, (20100429), pages 1 - 79, XP055751523-
OPPOSITION- Anonymous, "Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)", Clinicaltrials.gov, (20100513), pages 1 - 7, URL: https://clinicaltrials.gov/ct2/show/study/NCT00903422, XP055751561-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - Promacta", GlaxoSmithKline, (20080000), pages 1 - 21, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf, (20200814), XP055751403-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - Promacta", GlaxoSmithKline, (20080000), pages 1 - 21, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf, XP055751403-
OPPOSITION- Anonymous, "Platelet Count", MedlinePlus Medical Encyclopedia, (20200804), pages 1 - 4, URL: http://medlineplus.gov/ency/article/003647.htm, XP055751374-
OPPOSITION- Anonymous, "Revolade 25 mg film-coated tablets", Novartis Pharmaceuticals UK Ltd, (20200817), URL: https://www.medicines.org.uk/emc/product/7819/smpc/print-
OPPOSITION- Anonymous, "Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 March 2010 to 30June 2010", Official Journal of the European Union , C 258, (20100924), vol. 53, pages 2pp, C 258/1 - C 258/2, XP055751435-
OPPOSITION- Anonymous, "Union Register of medicinal products for human use / Product Information Revolade", European Commission, (20200727), pages 1 - 6, URL: https://ec.europa.eu/health/documents/community-register/html/h612.htm, XP055751423-
OPPOSITION- "Eltrombopag olamine | C29H36N6O6", PubChem Compound, (20190115), Database accession no. CID 135449331, URL: NCBI, XP055751533-
OPPOSITION- Glaxosmithkline, "SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy", ClinicalTrials.gov, (20170323), pages 1 - 8, URL: https://clinicaltrials.gov/ct2/show/NCT00102726, XP055751394-
OPPOSITION- S. P. Chawla , A. P. Staddon , C. Messam, A. M. Graham . Y. M. Mostafa Kamel, "An open-label, dose-ranging study to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide.", Journal of Clinical Oncology, vol. 28, no. Suppl.15, (20100520), URL: https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.tps334-
OPPOSITION- S. P. Chawla , A. P. Staddon , C. Messam, A. M. Graham . Y. M. Mostafa Kamel, "An open-label, dose-rangingstudy to assess the safety, efficacy, and pharmacokinetics of eltrombopag in treating thrombocytopenia in patients with advanced sarcomas receiving doxorubicin and ifosfamide", Journal of Clinical Oncology, vol. 28, no. Suppl.15, (20100526), URL: https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.tps334-
OPPOSITION- Zhang X, Chuai Y, Nie W, Wang A, Dai G, "Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours", Cochrane Database of Systematic Reviews, (20170000), no. 11, pages i-ii, 1 - 51, XP055751381-
OPPOSITION- Gemma Matthys, Jung Wook Park, Sandra Mcguire, Mary Beth Wire, Jianping Zhang, Carolyn Bowen, Daphne Williams, Julian M. Jenkins, Bin Peng, "Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects", British Journal of Pharmacolog y, (20100224), vol. 70, no. 1, pages 24 - 33, XP055751538
OPPOSITION- Julian M Jenkins; Daphne Williams; Yanli Deng; Joanne Uhl; Valerie Kitchen; David Collins; and Connie L Erickson-Miller, "Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist", Blood, (20070601), vol. 109, no. 11, pages 4739 - 4741, XP008147185
SEARCH- BUSSEL JAMES B ET AL, "Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: Results of four randomized, placebo-controlled studies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20071101), vol. 110, no. 11, Part 1, ISSN 0006-4971, page 391A, XP009164945 [I] 1-11 * abstract *-
SEARCH- DMYTRIJUK A ET AL, "Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura", ONCOLOGY, PRR, HUNTINGTON, NY, US, (20091130), vol. 23, no. 13, ISSN 0890-9091, pages 1171 - 1177, XP009164946 [AP] 1-11 * table 3 *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents